Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

06 janv. 2026 07h30 HE | Source: Silexion Therapeutics Corp

Silexion Therapeutics Releases CEO Letter to Shareholders Highlighting 2025’s Significant Achievements and Outlining Upcoming Milestones for 2026

SIL204 Demonstrated Significant Tumor Inhibition in Positive Pre Clinical Studies with Activity Across Pancreatic, Colorectal, and Lung Cancer Models Company’s Platform Seeks to Address an Estimated...
05 janv. 2026 10h37 HE | Source: Research and Markets

Precision Medicine Collaboration and Licensing Agreements Analysis Report 2025 with Directory of 1,221 Deals Signed Since 2019 by Company A-Z, Deal Type and Therapy Area

Dublin, Jan. 05, 2026 (GLOBE NEWSWIRE) -- The "Precision Medicine Collaboration and Licensing Deals 2019-2025" report has been added to ResearchAndMarkets.com's offering. This report contains a...
05 janv. 2026 08h31 HE | Source: Medzown

Medzown Appoints Dr. Jennifer Malin as Chief Medical Officer

BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Medzown (“Medzown” or the “Company”), a precision medicine management company focused on improving access to advanced therapies and clinical trials for...
16 déc. 2025 10h36 HE | Source: Research and Markets

How Whole Genome Amplification is Transforming Genomic Research and Diagnostics: Market Trends and Innovations

Dublin, Dec. 16, 2025 (GLOBE NEWSWIRE) -- The "Whole Genome Amplification (WGA) - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Whole...
16 déc. 2025 08h40 HE | Source: Silexion Therapeutics Corp

Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for SIL204 in Locally Advanced Pancreatic Cancer

Regulatory submission marks a significant milestone as the Company advances toward Phase 2/3 trial initiation in Q2 2026 at full speed Application follows recent successful toxicology studies,...
09 déc. 2025 08h30 HE | Source: SNS Insider pvt ltd

Omics-Based Clinical Trials Market to Surpass USD 61.98 Billion by 2032 Driven by Precision Medicine and Multi-Omics Integration – SNS Insider

Austin, Texas, Dec. 09, 2025 (GLOBE NEWSWIRE) -- According to SNS Insider, The Omics-based Clinical Trials Market size was valued at USD 32.75 billion in 2024 and is expected to reach USD 61.98...
02 déc. 2025 08h00 HE | Source: Silexion Therapeutics Corp

Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer

Positive feedback reinforces Silexion’s trajectory toward its planned Phase 2/3 trial initiation in Q2 2026 Company plans to complete regulatory submissions to the Israeli Ministry of Health by the...
26 nov. 2025 07h30 HE | Source: Research and Markets

Genomics Collaboration and Licensing Agreements Trends Analysis Report 2025 with Directory of 639 Deals Signed Since 2018 by Company A-Z, Therapy Focus and Technology Type

Dublin, Nov. 26, 2025 (GLOBE NEWSWIRE) -- The "Genomic Collaboration and Licensing Deals 2018-2025" has been added to ResearchAndMarkets.com's offering.The report contains a comprehensive listing...
26 nov. 2025 07h30 HE | Source: Silexion Therapeutics Corp

Silexion Therapeutics to Present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference

Grand Cayman, Cayman Islands, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage, oncology-focused biotechnology company, today announced...
25 nov. 2025 09h25 HE | Source: Research and Markets

Precision Medicine Strategic Intelligence Report 2025: Opportunities in Integrating AI and Bioinformatics to Predict Disease Risks, Enhance Diagnostics, and Shape Personalized Care

Dublin, Nov. 25, 2025 (GLOBE NEWSWIRE) -- The "Strategic Intelligence: Precision Medicine (2025)" report has been added to ResearchAndMarkets.com's offering.Precision medicine is revolutionizing...

Page suivante